IMS 2022 | Using flow cytometry to detect abnormal plasma cells in MGUS & predict disease progression
Jón Þórir Óskarsson
• 27 Aug 2022
Jón Þórir Óskarsson, MSc, University of Iceland, Reykjavik, Iceland, comments on the use of next-generation flow cytometry to detect abnormal plasma cells in patients with monoclonal gammopathy of undetermined significance (MGUS) and help better identify patients at risk of progression to active disease who require active monitoring. This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
